SI-Bone Inc (NASDAQ:SIBN) Chairman Jeffrey W. Dunn sold 1,436 shares of the company’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $20.16, for a total transaction of $28,949.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
SIBN stock opened at $19.73 on Monday. The stock’s 50-day moving average price is $18.45. The company has a debt-to-equity ratio of 0.47, a quick ratio of 12.70 and a current ratio of 13.06. SI-Bone Inc has a 52-week low of $14.08 and a 52-week high of $23.03. The stock has a market cap of $484.65 million and a price-to-earnings ratio of -27.79.
SI-Bone (NASDAQ:SIBN) last posted its earnings results on Wednesday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.13). The firm had revenue of $14.99 million for the quarter. On average, research analysts expect that SI-Bone Inc will post -1.45 EPS for the current year.
Several hedge funds have recently bought and sold shares of SIBN. Legal & General Group Plc purchased a new stake in shares of SI-Bone during the 4th quarter worth about $27,000. Citigroup Inc. purchased a new stake in shares of SI-Bone during the 4th quarter worth about $46,000. Valeo Financial Advisors LLC purchased a new stake in shares of SI-Bone during the 1st quarter worth about $94,000. American International Group Inc. purchased a new stake in shares of SI-Bone during the 4th quarter worth about $115,000. Finally, Deutsche Bank AG purchased a new stake in shares of SI-Bone during the 4th quarter worth about $227,000. 38.89% of the stock is currently owned by institutional investors and hedge funds.
SIBN has been the topic of several recent research reports. Zacks Investment Research lowered shares of Yatra Online from a “hold” rating to a “sell” rating in a report on Saturday, July 6th. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. SI-Bone presently has a consensus rating of “Buy” and a consensus price target of $24.75.
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Further Reading: Google Finance Portfolio
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.